Pediatric Clinic, Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, viale Golgi 19, 27100, Pavia, Italy.
Allergy Clinic, Casa di Cura Villa Montallegro, Genova, Italy.
Paediatr Drugs. 2020 Jun;22(3):295-310. doi: 10.1007/s40272-020-00387-2.
During the past decade, significant therapeutic progress has been made in the field of allergic diseases, mainly concerning the pathogenic role of type 2 inflammation. Biologics targeting specific key cytokines, such as interleukin (IL)-4, IL-5, and IL-13, as well as IgE, have emerged as promising innovative therapies for allergic disorders. In this context, dupilumab has emerged as one of the most successful therapies targeting the IL-4R axis. Dupilumab is a human IgG4 antibody anti-IL-4 receptor (IL-4R) α-subunit that blocks IL-4R signaling induced by both IL-4 and IL-13, downregulating the molecular pathways that drive type 2 inflammatory diseases, including atopic dermatitis, allergic rhinitis, allergic asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. This review presents the most recent evidence on dupilumab for the treatment of type 2 inflammatory diseases and discusses the future perspective, focusing on the pediatric age group and adolescents.
在过去的十年中，过敏疾病领域取得了重大的治疗进展，主要涉及 2 型炎症的发病机制。针对特定关键细胞因子（如白细胞介素 (IL)-4、IL-5 和 IL-13）以及 IgE 的生物制剂已成为治疗过敏疾病的有前途的创新疗法。在这种情况下，度普利尤单抗已成为针对 IL-4R 轴的最成功的治疗方法之一。度普利尤单抗是一种针对白细胞介素-4 受体 (IL-4R)α亚基的人 IgG4 抗体抗 IL-4R，可阻断由 IL-4 和 IL-13 诱导的 IL-4R 信号传导，下调驱动 2 型炎症性疾病的分子途径，包括特应性皮炎、过敏性鼻炎、过敏性哮喘、伴有鼻息肉的慢性鼻-鼻窦炎和嗜酸性食管炎。本文综述了度普利尤单抗治疗 2 型炎症性疾病的最新证据，并讨论了未来的展望，重点关注儿科和青少年人群。
